Camsirubicin is under clinical development by Monopar Therapeutics and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData, Phase II drugs for Soft Tissue Sarcoma have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Camsirubicin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
camsirubicin is under development for the treatment of advanced soft tissue sarcoma. The drug candidate is a 5-imino-13-deoxydoxorubicin and non-cardiotoxic analog of doxorubicin. It is administered through intravenous route for soft tissue sarcoma, oral route for other additional dermal formulations and applied topically for psoriasis. The drug candidate acts by targeting topoisomerase II alpha.
Monopar Therapeutics overview
Monopar Therapeutics (Monopar) is a clinical-stage biopharmaceutical company. It focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company’s pipeline products include validive, for chemoradiation induced SOM; camsirubicin, to treat advanced soft tissue sarcoma; MNPR-101 RIT, to treat advanced solid cancers, severe COVID-19; MNPR-101to treat solid cancers; MNPR-202, to treat advanced solid cancers. The company’s lead drug product candidate enters clinical development through collaboration with research center in the UK. It also carries out various phases of clinical trials. The company’s brands include Validive. Monopar is headquartered in Wilmette, Illinois, the US.
For a complete picture of Camsirubicin’s drug-specific PTSR and LoA scores, buy the report here.